Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 11:9:1310.
doi: 10.3389/fimmu.2018.01310. eCollection 2018.

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Affiliations
Review

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Rebekka Weber et al. Front Immunol. .

Abstract

Immune checkpoint inhibitors (ICI) used for cancer immunotherapy were shown to boost the existing anti-tumor immune response by preventing the inhibition of T cells by tumor cells. Antibodies targeting two negative immune checkpoint pathways, namely cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death-ligand 1 (PD-L1), have been approved first for patients with melanoma, squamous non-small cell lung cancer (NSCLC), and renal cell carcinoma. Clinical trials are ongoing to verify the efficiency of these antibodies for other cancer types and to evaluate strategies to block other checkpoint molecules. However, a number of patients do not respond to this treatment possibly due to profound immunosuppression, which is mediated partly by myeloid-derived suppressor cells (MDSC). This heterogeneous population of immature myeloid cells can strongly inhibit anti-tumor activities of T and NK cells and stimulate regulatory T cells (Treg), leading to tumor progression. Moreover, MDSC can contribute to patient resistance to immune checkpoint inhibition. Accumulating evidence demonstrates that the frequency and immunosuppressive function of MDSC in cancer patients can be used as a predictive marker for therapy response. This review focuses on the role of MDSC in immune checkpoint inhibition and provides an analysis of combination strategies for MDSC targeting together with ICI to improve their therapeutic efficiency in cancer patients.

Keywords: cancer immunotherapy; combination therapy; immune checkpoint inhibition; immunosuppression; myeloid-derived suppressor cells.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Mechanism of immune checkpoint inhibitors (ICI) in combination with myeloid-derived suppressor cell (MDSC) neutralization. In the tumor microenvironment, tumor and antigen-presenting cells express the ligands for programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 receptors on T cells. Signals transmitted via these receptors induce a T cell arrest and the termination of the anti-tumor immune response. Blockade of these negative checkpoint molecules can restore the anti-tumor activity of T cells. However, MDSC can induce T cell inhibition by mechanisms different from negative checkpoint molecules. The combination of MDSC inhibition with ICI could further increase T cell-mediated anti-tumor immune responses and the clinical outcome of cancer patients.

References

    1. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 14:73.10.1186/s12916-016-0623-5 - DOI - PMC - PubMed
    1. Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL, et al. Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer (2017) 81:116–29.10.1016/j.ejca.2017.01.035 - DOI - PubMed
    1. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res (2013) 19:4917–24.10.1158/1078-0432.CCR-12-1972 - DOI - PMC - PubMed
    1. Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist (2008) 13(Suppl 4):2–9.10.1634/theoncologist.13-S4-2 - DOI - PubMed
    1. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711–23.10.1056/NEJMoa1003466 - DOI - PMC - PubMed